Newsroom

Dendrogenix, an innovative biotechnology company based in Liège (Belgium) announced today positive results from its first Phase 1 clinical trial evaluating its drug candidate DX243. Building on these encouraging data, the company plans to initiate a Phase 2a clinical trial in the first quarter of 2026 in the field of age-related hearing loss (presbycusis). Located at the heart of the biomedical research ecosystem of CHU Sart-Tilman and GIGA Neuroscience, Dendrogenix is developing a novel proprietary class of compounds called “Dendrogenin”, with DX243 as its first clinical candidate. These compounds are intended for the treatment of neurodegenerative diseases, with a particular focus on age-related auditory disorders.

Phase 1 clinical results: excellent tolerability supporting ...

We are pleased to announce that Dendrogenix will be attending BIO-Europe 2025 in Vienna, November 3–5. As one of Europe’s leading partnering events for the biopharma industry, BIO-Europe brings together biotech innovators, pharmaceutical companies, and investors to foster new collaborations and accelerate life science innovation. Our team will be presenting our ongoing clinical development programs and exploring strategic partnerships and private funding opportunities to advance our pipeline.

Dendrogenix team had the pleasure of participating in the Sambrinvest Bio Investment Convention on October 16, 2025 , where innovation, entrepreneurship, and investment came together to spark new opportunities. We had the chance to present our mission to develop cutting-edge innovative therapies in hearing-loss area and to connect with passionate investors and partners who share our vision for improving patients’ lives. A big thank you to Sambrinvest for organizing such a high-impact event and to everyone who stopped by to discuss science, strategy, and growth with us.

We’re excited to share that Dendrogenix will take part in the upcoming Sambrinvest Bio Investment Convention on October 16, 2025, a key event bringing together innovative companies and forward-thinking investors in the Wallonia region. This convention offers a valuable opportunity for us to showcase our progress in developing next-generation neuroprotective and neuroregenerative therapies in the field of Hearing Loss, and to connect with partners who share our vision for transforming patient care. Our team looks forward to engaging discussions on our clinical and strategic milestones, while exploring new avenues for collaboration and investment to fuel the next stage of our growth.

Dr. Quentin Marlier, head of biology at Dendrogenix and ESO member, will present a poster publication entitled “Improvement of neurological outcomes following Stroke in mice treated with a novel first-in-class compound” to expose preclinical data regarding its lead compound DX243 in Stroke. European Stroke Organisation Conference (ESOC) is Europe’s leading forum for advances in research and clinical care of patients with cerebrovascular diseases. ESOC 2025 will take place from 21–23 May 2025 in Helsinki, Finland.